IQVIA HOLDINGS INC. (IQV) Current Ratio
- Current ratio · latest quarter: Value 0.75×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.75× | Current assets / current liabilities. $6.22B ÷ $8.33B ≈ 0.75× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 6.22B USD | Assets, Current |
| Current obligations | 8.33B USD | Liabilities, Current |
| Cash and equivalents | 1.95B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 156.00M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | 1.84B USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $6.22B | $8.33B | $1.95B | $156.00M | (m) | (m) | (m) | $1.84B | 0.75× |
| 2025-12-31 | $6.25B | $8.34B | $1.98B | $161.00M | (m) | (m) | (m) | $1.84B | 0.75× |
| 2025-09-30 | $5.98B | $8.51B | $1.81B | $158.00M | (m) | (m) | (m) | $2.16B | 0.70× |
| 2025-06-30 | $6.34B | $7.57B | $2.04B | $149.00M | (m) | (m) | (m) | $1.31B | 0.84× |
| 2025-03-31 | $5.91B | $7.18B | $1.74B | $136.00M | (m) | (m) | (m) | $1.22B | 0.82× |
| 2024-12-31 | $5.83B | $6.96B | $1.70B | $141.00M | (m) | (m) | (m) | $1.15B | 0.84× |
| 2024-09-30 | $5.63B | $6.99B | $1.57B | $140.00M | (m) | (m) | (m) | $1.22B | 0.81× |
| 2024-06-30 | $5.62B | $6.62B | $1.54B | $133.00M | (m) | (m) | (m) | $1.17B | 0.85× |
| 2024-03-31 | $5.65B | $6.45B | $1.44B | $131.00M | (m) | (m) | (m) | $717.00M | 0.88× |
| 2023-12-31 | $5.60B | $6.49B | $1.38B | $120.00M | (m) | (m) | (m) | $718.00M | 0.86× |
| 2023-09-30 | $5.21B | $6.59B | $1.22B | $108.00M | (m) | (m) | (m) | $1.31B | 0.79× |
| 2023-06-30 | $5.33B | $6.54B | $1.38B | $110.00M | (m) | (m) | (m) | $1.34B | 0.81× |
| 2023-03-31 | $5.33B | $6.66B | $1.49B | $104.00M | (m) | (m) | (m) | $1.34B | 0.80× |
| 2022-12-31 | $4.98B | $5.58B | $1.22B | $93.00M | (m) | (m) | (m) | $152.00M | 0.89× |
| 2022-09-30 | $4.75B | $5.25B | $1.27B | $87.00M | (m) | (m) | (m) | $151.00M | 0.90× |
| 2022-06-30 | $4.91B | $5.10B | $1.43B | $90.00M | (m) | (m) | (m) | $152.00M | 0.96× |
| 2022-03-31 | $4.77B | $5.16B | $1.39B | $106.00M | (m) | (m) | (m) | $90.00M | 0.93× |
| 2021-12-31 | $4.76B | $5.24B | $1.37B | $111.00M | (m) | (m) | (m) | $91.00M | 0.91× |
| 2021-09-30 | $4.53B | $4.85B | $1.47B | $104.00M | (m) | (m) | (m) | $91.00M | 0.94× |
| 2021-06-30 | $5.07B | $4.82B | $1.81B | $104.00M | (m) | (m) | (m) | $147.00M | 1.05× |
| 2021-03-31 | $5.58B | $4.87B | $2.31B | $97.00M | (m) | (m) | (m) | $144.00M | 1.15× |
| 2020-12-31 | $5.09B | $4.56B | $1.81B | $88.00M | (m) | (m) | (m) | $149.00M | 1.12× |
| 2020-09-30 | $4.64B | $4.14B | $1.46B | $79.00M | (m) | (m) | (m) | $144.00M | 1.12× |
| 2020-06-30 | $4.21B | $3.84B | $1.11B | $73.00M | (m) | (m) | (m) | $142.00M | 1.09× |
| 2020-03-31 | $4.28B | $3.91B | $927.00M | $63.00M | (m) | (m) | (m) | $139.00M | 1.09× |
| 2019-12-31 | $4.13B | $3.94B | $837.00M | $62.00M | (m) | (m) | (m) | $100.00M | 1.05× |
| 2019-09-30 | $4.00B | $3.58B | $863.00M | $57.00M | (m) | (m) | (m) | $98.00M | 1.12× |
| 2019-06-30 | $3.98B | $3.50B | $938.00M | $56.00M | (m) | (m) | (m) | $100.00M | 1.14× |
| 2019-03-31 | $4.00B | $3.50B | $936.00M | $55.00M | (m) | (m) | (m) | $100.00M | 1.14× |
| 2018-12-31 | $3.87B | $3.53B | $891.00M | $47.00M | (m) | (m) | (m) | $100.00M | 1.10× |
| 2018-09-30 | $3.70B | $3.38B | $827.00M | (m) | (m) | (m) | (m) | $101.00M | 1.09× |
| 2018-06-30 | $3.59B | $3.17B | $879.00M | (m) | (m) | (m) | (m) | $101.00M | 1.13× |
| 2018-03-31 | $3.72B | $3.20B | $960.00M | (m) | (m) | (m) | (m) | $104.00M | 1.16× |
| 2017-12-31 | $3.55B | $3.16B | $959.00M | $46.00M | (m) | (m) | $322.00M | $103.00M | 1.13× |
| 2017-09-30 | $3.49B | $2.85B | $1.10B | (m) | (m) | (m) | (m) | $103.00M | 1.22× |
| 2017-06-30 | $3.26B | $2.66B | $902.00M | (m) | (m) | (m) | (m) | $94.00M | 1.23× |
| 2017-03-31 | $3.12B | $2.60B | $862.00M | (m) | (m) | (m) | (m) | $91.00M | 1.20× |
| 2016-12-31 | $3.34B | $2.71B | $1.20B | (m) | (m) | (m) | $250.00M | $92.00M | 1.23× |
| 2016-09-30 | $2.64B | $1.62B | $1.21B | (m) | (m) | (m) | (m) | (m) | 1.63× |
| 2016-06-30 | $2.44B | $1.60B | $955.68M | (m) | (m) | (m) | (m) | (m) | 1.52× |
| 2016-03-31 | $2.44B | $1.58B | $1.05B | (m) | (m) | (m) | (m) | (m) | 1.54× |
| 2015-12-31 | $2.41B | $1.59B | $977.00M | (m) | (m) | (m) | $145.00M | $49.00M | 1.51× |
| 2015-09-30 | $2.52B | $1.52B | $1.08B | (m) | (m) | (m) | (m) | $48.50M | 1.65× |
| 2015-06-30 | $2.22B | $1.35B | $803.62M | (m) | (m) | (m) | (m) | $48.50M | 1.64× |
| 2015-03-31 | $2.10B | $1.32B | $779.07M | (m) | (m) | (m) | (m) | (m) | 1.59× |
| 2014-12-31 | $2.15B | $1.47B | $867.36M | (m) | (m) | (m) | $108.74M | $750.00K | 1.46× |
| 2014-09-30 | $1.94B | $1.43B | $645.03M | (m) | (m) | (m) | (m) | (m) | 1.36× |
| 2014-06-30 | $1.86B | $1.35B | $636.47M | (m) | (m) | (m) | (m) | (m) | 1.38× |
| 2014-03-31 | $1.95B | $1.38B | $741.38M | (m) | (m) | (m) | (m) | (m) | 1.42× |
| 2013-12-31 | $1.95B | $1.48B | $778.14M | (m) | (m) | (m) | $100.62M | $10.31M | 1.31× |
| 2013-09-30 | $1.72B | $1.33B | $609.71M | (m) | (m) | (m) | (m) | (m) | 1.29× |
| 2013-06-30 | $1.67B | $1.24B | $585.72M | (m) | (m) | (m) | (m) | (m) | 1.35× |
| 2013-03-31 | $1.44B | $1.22B | $454.29M | (m) | (m) | (m) | (m) | (m) | 1.18× |
| 2012-12-31 | $1.51B | $1.31B | $567.73M | (m) | (m) | (m) | $84.71M | $55.59M | 1.15× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |